Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Get an expert&rsquo s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this program which features a series of ClinicalThought&trade commentaries on emerging clinical data managing immune-related adverse events and key biomarkers of response.

Share

Program Content

Activities

ICIs for Gastroesophageal Cancers
Immune Checkpoint Inhibitors for Advanced Gastroesophageal Cancers: Key Findings From ASCO GI 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2019

Expires: February 25, 2020

irAEs in Gastric-GEJ
Identifying and Managing Immune-Related Adverse Events in Patients With Advanced Gastroesophageal Cancers Receiving Checkpoint Inhibitors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2019

Expires: March 20, 2020

ICIs in Gastric/GEJ
How I Use Checkpoint Inhibitors in Later-line Advanced Gastric/GEJ Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2019

Expires: July 16, 2020

Faculty

cover img faculity

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

cover img faculity

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb